Tumor angiogenesis - A new therapeutic target in gliomas

Acta Neurologica Scandinavica

Volumn 97, Issue 1, 1998, Pages 52-62

  Lund, E L ^a   Spang Thomsen, M ^a   Skovgaard Poulsen, H ^b   Kristjansen, P E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Angiogenesis; Anti aogiogenic therapy; Brain tumors; CNS; Glioblastoma multiforme

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BATIMASTAT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCOCORTICOID; GROWTH FACTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT VASCULOTROPIN; SURAMIN; THALIDOMIDE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; EXPERIMENTAL MODEL; GLIOBLASTOMA; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NEURILEMOMA; NEUROFIBROSARCOMA; NONHUMAN; RAT; TUMOR GROWTH;

EID: 0031974373     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb00609.x     Document Type: Article

References (71)

1. FOLKMAN J. Tumor angiogenesis: Therapeutic implications. Review. N Engl J Med 1971: 285(21): 1182-6.
2. FOLKMAN J. Fighting cancer by attacking its blood supply. [Review]. Sci Am 1996: 275: 150-4.
3. HANAHAN D, FOLKMAN J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. [Review.] Cell 1996: 86: 353-64.
4. YUAN F, SALEHI HA, BOUCHER Y, VASTHARE US, TUMA RF, JAIN RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994: 54: 4564-8.
5. COCKERILL GW, GAMBLE JR, VADAS MA. Angiogenesis: models and modulators. [Review.] Int Rev Cytol 1995: 159: 113-60.
6. DELLIAN M, WITWER BP, SALEHI HA, YUAN F, JAIN RK. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment [see comments]. Am J Pathol 1996: 149: 59-71.
7. FOLKMAN J, SHING Y. Angiogenesis. [Review.] J Biol Chem 1992: 267: 10931-4.
8. FOLKMAN J. Tumor angiogenesis; in Anonymous Cancer Medicine. Philadelphia, London: Lea & Fibinger, 1993, pp 153-70.
9. BATTEGAY EJ, RUPP J, IRUELA-ARISPE L, SAGE EH, PECH M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 1994: 125: 917-28.
10. PLATE KH, BREIER G, FARRELL CL, RISAU W. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992: 67: 529-34.
11. HERMANSON M, FUNA K, HARTMAN M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992: 52: 3213-9.
12. WEINER HL. The role of growth factor receptors in central nervous system development and neoplasia. [Review.] Neurosurgery 1995: 37: 179-93: discussion 193-4.
13. GOLDMAN CK, KIM J, WONG WL, KING V, BROCK T, GILLESPIE GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993: 4: 121-33.
14. ZAGZAG D. Angiogenic growth factors in neural embryogenesis and neoplasia. [Review.] Am J Pathol 1995: 146: 293-309.
15. SCHREIBER AB, WINKLER ME, DERYNCK R. Transforming growih factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986: 232: 1250-3.
16. NORGAARD P, HOUGAARD S, POULSEN HS, SPANG-THOMSEN M. Transforming growth factor beta and cancer. [Review.] Cancer Treat Rev 1995: 21: 367-403.
17. FAJARDO LF, PRIONAS SD, KWAN HH, KOWALSKI J, ALLISON AC. Transforming growth factor beta I induces angiogenesis in vivo with a threshold pattern. Lab Invest 1996: 74: 600-8.
18. KOOLWIJK P, VAN ERCK MG, DE VREE WJ et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996: 132: 1177-88.
19. SURI C, JONES PF, PATAN S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comments]. Cell 1996: 87: 1171-80.
20. TAYLOR CM, WEISS JB, LYE RH. Raised levels of latent collagenase activating angiogenesis factor (ESAF) are present in actively growing human intracranial tumours. Br J Cancer 1991: 64: 164-8.
21. 121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 1996: 271: 5519-23.
22. SAMOTO K, IKEZAKI K, ONO M et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995: 55: 1189-93.
23. STRUGAR J, ROTHBART D, HARRINGTON W, CRISCUOLO GR. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994: 81: 560-6.
24. STRUGAR JG, CRISCUOLO GR, ROTHBART D, HARRINGTON WN. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995: 83: 682-9.
25. PLATE KH, BREIER G, WEICH HA, RISAU W. Vascular endothelial growth factor as a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992: 359: 845-8.
26. HATVA E, KAIPAINEN A, MENTULA P et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995: 146: 368-78.
27. PLATE KH, BREIER G, WEICH HA, MENNEL HD, RISAU W. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994: 59: 520-9.
28. YAMANE A, SEETHARAM L, YAMAGUCHI S et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994: 9: 2683-90.
29. ALON T, HEMO I, ITIN A, PE'ER J, STONE J, KESHET E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995: 1: 1024-8.
30. SHWEIKI D, ITIN A, SOFFER D, KESHET E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992: 359: 843-5.
31. SHWEIKI D, NEEMAN M, ITIN A, KESHET E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Nat Acad Sci USA 1995: 92: 768-72.
32. KIM KJ, LI B, WINER J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993: 362: 841-4.
33. MILLAUER B, SHAWVER LK, PLATE KH, RISAU W, ULLRICH A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994: 367: 576-9.
34. SALEH M, STACKER SA, WILKS AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996: 56: 393-401.
35. KUKK E, LYMBOUSSAKI A, TAIRA S et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996: 122: 3829-37.
36. BREM S, TSANACLIS AM, GATELY S, GROSS JL, HERBLIN WF. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 1992: 70: 2673-80.
37. STEFANIK DF, RIZKALLA LR, SOI A, GOLDBLATT SA, RIZKALLA WM. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991: 51: 5760-5.
38. TAKAHASHI JA, MORI H, FUKUMOTO M et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Nat Acad Sci USA 1990: 87: 5710-14.
39. ZAGZAG D, MILLER DC, SATO Y, RIFKIN DB, BURSTEIN DE. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 1990: 50: 7393-8.
40. PAULUS W, GROTHE C, SENSENBRENNER M et al. Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol 1990: 79: 418-23.
41. ASAHARA T, BAUTERS C, ZHENG LP et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995: 92: (9 Suppl)II365-71.
42. STAN AC, NEMATI MN, PIETSCH T, WALTER GF, DIETZ H. In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 1995: 82: 1044-52.
43. MORRISON RS, YAMAGUCHI F, BRUNER JM, TANG M, MCKEEHAN W, BERGER MS. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994: 54: 2794-9.
44. DEL MAESTRO RF, VAITHILINGAM IS, MCDONALD W. Degradation of collagen type IV by C6 astrocytoma cells. J Neurooncol 1995: 24: 75-81.
45. HSU DW, EFIRD JT, HEDLEY-WHYTE ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995: 147: 114-23.
46. YAMAMOTO M, SAWAYA R, MOHANAM S et al. Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. [Review.] J Neurooncol 1994: 22: 139-51.
47. WOLFF JE, GUERIN C, LATERRA J et al. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 1993: 604: 79-85.
48. ZAGZAG D, FRIEDLANDER DR, DOSIK J et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996: 56: 182-9.
49. ZAGZAG D, FRIEDLANDER DR, MILLER DC et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995: 55: 907-14.
50. FOLKMAN J. Angiogenesis in cancer, vascular, rheumatoid and other disease. [Review.] Nat Med 1995; 1: 27-31.
51. O'REILLY MS, HOLMGREN L, SHING Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994: 79: 315-28.
52. ROBERTS DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996: 10: 1183-91.
53. CLAPP C, MARTIAL JA, GUZMAN RC, RENTIER-DELURE F, WEINER RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993: 133: 1292-9.
54. ZUCKLER MB, KATZ IR. Platelet factor 4: production, structure, and physiologic and immunologic action. [Review.] Proc Soc Exp Biol Med 1991: 198: 693-702.
55. FOLKMAN J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments]. [Review.] N Engl J Med 1995: 333: 1757-63.
56. HANNEKEN A, YING W, LING N, BAIRD A. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Nat Acad Sci USA 1994: 91: 9170-4.
57. VAN MEIR EG, POLVERINI PJ, CHAZIN VR, SU HUANG HJ, DE TRIBOLET N, CAVENEE WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994: 8: 171-6.
58. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994: 265: 1582-4.
59. ASANO M, YUKITA A, MATSUMOTO T, KONDO S, SUZUKI H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 1995: 55: 5296-301.
60. RAMAKRISHNAN S, OLSON TA, BAUTCH VL, MOHANRAJ D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996: 56: 1324-30.
61. HORI A, IKEYAMA S, SUDO K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun 1994: 204: 1067-73.
62. TAKAMIYA Y, BREM H, OJEIFO J, MINETA T, MARTUZA RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and m vivo. Neurosurgery 1994: 34: 869-75; discussion 875.
63. TAKAMIYA Y, FRIEDLANDER RM, BREM H, MALICK A, MARTUZA RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993: 78: 470-6.
64. WILSON JT, PENAR PL. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol Res 1994: 16: 121-4.
65. HAWKINS MJ. Clinical trials of antiangiogenic agents. [Review.] Curr Opin Oncol 1995: 7: 90-3.
66. WOJTOWICS-PRAGA S, LOW J. Phase 1 trial of a novel metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996: 14: 193-202.
67. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J. Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA 1994: 91: 4082-5.
68. TAKAHASHI JA, FUKUMOTO M, KOZAI Y et al. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 1991: 288: 65-71.
69. YAZAKI T, TAKAMIVA Y, COSTELLO PC et al. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neuroncol 1995: 23: 23-9.
70. TEICHER BA, SOTAMAYOR EA, HUANG ZD. Antiangiogenetic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992: 52(23): 6702-4.
71. DING I, HUANG K, SNYDER ML et al. Tumor growth and tumor radiosensitivity in mice given myeloprotective doses of fibroblast growth factors. J Nat Cancer Inst 1996: 88: 1399-1404.